Adalvo And Sinopep Establish Strategic Partnership Across GLP-1 And Oligonucleotide Therapeutics

Adalvo and Sinopep Establish Strategic Partnership Across GLP-1 and Oligonucleotide Therapeutics. Strategic partnership expands capabilities across GLP-1 and oligonucleotide therapeutics, creating a scalable platform for the development and delivery of complex medicines worldwide.

Sinopep-Allsino Biopharmaceutical Co., Ltd. (“Sinopep”) and Adalvo today announced a strategic partnership focused on the development and commercialization of peptide and oligonucleotide therapeutics worldwide, including GLP-1 receptor agonists.The collaboration combines Sinopep’s scientific, development, and GMP manufacturing expertise with Adalvo’s global commercial, regulatory, and market access capabilities across more than 160 markets and a network of over 260 commercial partners. Together, the companies aim to accelerate the development and delivery of high-value therapies in some of the pharmaceutical industry’s fastest-growing and most innovative segments.

Founded in 2009, Sinopep has established itself as a trusted CDMO partner for complex peptides, oligonucleotides, and advanced pharmaceutical technologies, supporting global pharmaceutical companies from early development through commercial-scale manufacturing. The partnership is structured as a long-term platform rather than a single-product collaboration, leveraging shared infrastructure, coordinated development pathways, and scalable supply capabilities across multiple programs.Under the agreement, Sinopep will serve as the development and manufacturing partner, supporting programs from early-stage development through commercial supply. Adalvo will lead global commercial strategy, regulatory navigation, and partner engagement, utilizing its international platform to maximize the reach and value of each program.

Peptide therapeutics, including GLP-1 receptor agonists, continue to transform the treatment of cardiometabolic diseases, while oligonucleotide therapeutics offer highly targeted approaches across a growing range of indications. Together, these modalities represent significant long-term growth opportunities in the global pharmaceutical market.By combining complementary strengths, Adalvo and Sinopep intend to create a streamlined pathway from development through commercialization for a portfolio of complex therapies.

Our partnership with Sinopep reflects a shared vision for the future of complex medicines. Sinopep's vertically integrated capabilities across development, manufacturing and commercial supply, combined with Adalvo's global commercial, regulatory and market access platform, create a powerful pathway to accelerate the development and delivery of peptide and oligonucleotide therapies worldwide. Together, we are building a scalable platform designed to create value across multiple programmes, markets and therapeutic areas. Anil Okay - CEO, Adalvo

I believe both companies enjoy different areas of strength and expertise, hence complementary to each other for true win-win arrangements. Let’s believe in the growth brought by new products and new modalities of business development is infinite. Thomas Tong - CEO, Sinopep

By bringing together development excellence, manufacturing strength and global commercial reach, Adalvo and Sinopep are establishing a foundation for sustainable growth and future innovation.

About Sinopep
Sinopep-Allsino Biopharmaceutical Co., Ltd. is a leading worldwide commercial API supplier and full-service CDMO, delivering large-scale GMP manufacturing for peptides, oligonucleotides, and small molecules to support global biopharma partners from development through commercial supply. We provide established peptide capacity of multi-metric tons annually, proven commercial-scale production for small molecule generics and NCEs, and our new large-scale GMP oligonucleotide facility in Jiangsu Lianyungang capable of thousands of kilograms per year, including ASOs, siRNA, and advanced conjugates. With FDA-inspected facilities, strong regulatory expertise, and seamless end-to-end capabilities, Sinopep ensures reliable, high-quality, and cost-effective commercial API supply for innovative therapeutics worldwide.

About Adalvo
Adalvo is a leading global B2B pharmaceutical company, combining a differentiated portfolio with an end-to-end platform that brings complex generics, 505(b)(2) products, peptides, biosimilars and GLP-1s to market quickly and sustains reliable supply over the long term. From portfolio selection through development, regulatory and supply to commercial out-licensing, Adalvo partners with over 170 pharmaceutical companies across more than 140 countries, turning technical capability into repeatable, first-to-market delivery. Headquartered in Switzerland and backed by EQT, Adalvo is committed to making a difference for patients around the world.